SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Randall Susan)
 

Sökning: WFRF:(Randall Susan) > Methotrexate, Doxor...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005703naa a2200889 4500
001oai:lup.lub.lu.se:d28df80f-9433-4f99-98e7-bd5b425390d9
003SwePub
008160401s2015 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/75085152 URI
0247 a https://doi.org/10.1200/JCO.2014.60.07342 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Bielack, Stefan S4 aut
2451 0a Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
264 1c 2015
338 a electronic2 rdacarrier
520 a Purpose EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy. Patients and Methods At diagnosis, patients age ≤ 40 years with resectable high-grade osteosarcoma were registered. Eligibility after surgery for good response random assignment included ≥ two cycles of preoperative MAP (methotrexate, doxorubicin, and cisplatin), macroscopically complete surgery of primary tumor, < 10% viable tumor, and no disease progression. These patients were randomly assigned to four additional cycles MAP with or without IFN-α-2b (0.5 to 1.0 μg/kg per week subcutaneously, after chemotherapy until 2 years postregistration). Outcome measures were event-free survival (EFS; primary) and overall survival and toxicity (secondary). Results Good response was reported in 1,041 of 2,260 registered patients; 716 consented to random assignment (MAP, n = 359; MAP plus IFN-α-2b, n = 357), with baseline characteristics balanced by arm. A total of 271 of 357 started IFN-α-2b; 105 stopped early, and 38 continued to receive treatment at data freeze. Refusal and toxicity were the main reasons for never starting IFN-α-2b and for stopping prematurely, respectively. Median IFN-α-2b duration, if started, was 67 weeks. A total of 133 of 268 patients who started IFN-α-2b and provided toxicity information reported grade ≥ 3 toxicity during IFN-α-2b treatment. With median follow-up of 44 months, 3-year EFS for all 716 randomly assigned patients was 76% (95% CI, 72% to 79%); 174 EFS events were reported (MAP, n = 93; MAP plus IFN-α-2b, n = 81). Hazard ratio was 0.83 (95% CI, 0.61 to 1.12; P = .214) from an adjusted Cox model. Conclusion At the preplanned analysis time, MAP plus IFN-α-2b was not statistically different from MAP alone. A considerable proportion of patients never started IFN-α-2b or stopped prematurely. Long-term follow-up for events and survival continues.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Smeland, Sigbjørn4 aut
7001 a Whelan, Jeremy S4 aut
7001 a Marina, Neyssa4 aut
7001 a Jovic, Gordana4 aut
7001 a Hook, Jane M4 aut
7001 a Krailo, Mark D4 aut
7001 a Gebhardt, Mark4 aut
7001 a Pápai, Zsuzsanna4 aut
7001 a Meyer, James4 aut
7001 a Nadel, Helen4 aut
7001 a Randall, R Lor4 aut
7001 a Deffenbaugh, Claudia4 aut
7001 a Nagarajan, Rajaram4 aut
7001 a Brennan, Bernadette4 aut
7001 a Letson, G Douglas4 aut
7001 a Teot, Lisa A4 aut
7001 a Goorin, Allen4 aut
7001 a Baumhoer, Daniel4 aut
7001 a Kager, Leo4 aut
7001 a Werner, Mathias4 aut
7001 a Lau, Ching C4 aut
7001 a Sundby Hall, Kirsten4 aut
7001 a Gelderblom, Hans4 aut
7001 a Meyers, Paul4 aut
7001 a Gorlick, Richard4 aut
7001 a Windhager, Reinhard4 aut
7001 a Helmke, Knut4 aut
7001 a Eriksson, Mikaelu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-mer
7001 a Hoogerbrugge, Peter M4 aut
7001 a Schomberg, Paula4 aut
7001 a Tunn, Per-Ulf4 aut
7001 a Kühne, Thomas4 aut
7001 a Jürgens, Heribert4 aut
7001 a van den Berg, Henk4 aut
7001 a Böhling, Tom4 aut
7001 a Picton, Susan4 aut
7001 a Renard, Marleen4 aut
7001 a Reichardt, Peter4 aut
7001 a Gerss, Joachim4 aut
7001 a Butterfass-Bahloul, Trude4 aut
7001 a Morris, Carol4 aut
7001 a Hogendoorn, Pancras C W4 aut
7001 a Seddon, Beatrice4 aut
7001 a Calaminus, Gabriele4 aut
7001 a Michelagnoli, Maria4 aut
7001 a Dhooge, Catharina4 aut
7001 a Sydes, Matthew R4 aut
7001 a Bernstein, Mark4 aut
7102 a Tumörmikromiljöb Sektion I4 org
7730 t Journal of Clinical Oncologyg 33:20, s. 2279-2287q 33:20<2279-2287x 1527-7755
8564 u https://portal.research.lu.se/files/1692560/8560306x primaryx freey FULLTEXT
8564 u http://www.ncbi.nlm.nih.gov/pubmed/26033801?dopt=Abstractx freey FULLTEXT
8564 u http://dx.doi.org/10.1200/JCO.2014.60.0734x freey FULLTEXT
8564 8u https://lup.lub.lu.se/record/7508515
8564 8u https://doi.org/10.1200/JCO.2014.60.0734

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy